02:09 , Feb 3, 2018 |  BioCentury  |  Strategy

Road to acquisition

Sanofi’s proposed acquisition of Ablynx N.V. puts considerable value not only on the Belgian biotech’s lead hematology asset caplacizumab, but also on its Nanobody platform, which fits the pharma’s R&D strategy of prioritizing development of...
20:31 , Feb 2, 2018 |  BC Week In Review  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.8 billion). The price is a 21% premium to Ablynx's close of...
23:11 , Jan 29, 2018 |  BC Extra  |  Company News

Sanofi to acquire Ablynx in €3.9B deal

Sanofi (Euronext:SAN; NYSE:SNY) said it will acquire Nanobodies company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) for €45 per share in cash, or about €3.9 billion ($4.84 billion). The price is a 21% premium to Ablynx's close of...
00:02 , Jan 13, 2018 |  BioCentury  |  Finance

Assessing Ablynx

While a group of investors in Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) don’t agree on what is fair value for the Belgian biotech, they do think a $2.8 billion offer from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) undervalues...
18:24 , Jan 12, 2018 |  BC Week In Review  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) made public news that its board rejected two unsolicited acquisition proposals from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO). Ablynx said in a statement the latest proposal "fundamentally undervalues" the company. On Dec. 22,...
22:53 , Jan 8, 2018 |  BC Extra  |  Company News

Ablynx rejects Novo's $2.8B acquisition proposal

Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) gained €9.60 (45%) to €30.80 in Brussels and $12.71 (49%) to $38.62 in New York on Monday after making public news that its board rejected two unsolicited acquisition proposals from Novo...
21:52 , Oct 27, 2017 |  BioCentury  |  Finance

Ablynx’s ambitions

With this week's hefty NASDAQ financing, nanobody company Ablynx N.V. (Euronext:ABLX; NASDAQ:ABLX) not only broadened its U.S. investor base, but added high-quality shareholders that are pushing the company to be even more ambitious as it...
19:02 , Feb 22, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Cell culture and mouse studies identified llama-derived single-domain antibodies against RSV F protein that could help treat RSV. In a non-human primate cell-based assay of RSV-induced plaque formation, screening of recombinant...
16:14 , Jan 13, 2017 |  BC Week In Review  |  Clinical News

ALX-0171: Ph IIb RESPIRE started

Ablynx began the double-blind, placebo-controlled, international Phase IIb RESPIRE trial to evaluate 3, 6 and 9 mg/kg inhaled ALX-0171 once daily for 3 days in about 180 hospitalized infants ages 1-24 months with a lower...
00:53 , Jun 3, 2016 |  BC Extra  |  Financial News

Ablynx raises EUR 74.2 million

Antibody company Ablynx N.V. (Euronext:ABLX) raised EUR 74.2 million ($82.5 million) through a private placement of 5.5 million shares at EUR 13.40. The price is a 6% discount to Ablynx' close of EUR 14.30 on...